

Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029

<https://marketpublishers.com/r/GF9ED2C8979AEN.html>

Date: July 2023

Pages: 600

Price: US\$ 3,600.00 (Single User License)

ID: GF9ED2C8979AEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029
Report Highlights:

Global Peptide Drug Market Opportunity: > USD 15 Billion

Marketed Cancer Peptides Drugs Sales Insight 2019 – 2023

Marketed Cancer Peptides Drugs Dosage, Patent & Price Insight

Marketed Cancer Peptides Drugs Clinical & Commercial Insight: 25 Drugs

Peptide Cancer Drug Clinical Trials Insight: > 200 Drugs

Global Peptide Cancer Drug Clinical Trials Insight By Company, Country
Indication & Phase

Peptide Drug Development Proprietary Technologies By Company & Indication

Biologics have been an important class of drugs for several diseases including cancer. Till now, antibodies have dominated this domain of therapeutics but driven by new technological innovations, researchers have now shifted their new drug development approach towards peptides as preferred choice of anti-cancer agents. For a long time, peptides have been used as therapeutic agents; however, their potential in cancer has

been a new area of interest. Due to their ability to offer advanced optimization strategies, peptide drugs have become an attractive area of research.

The development of peptide based drugs and therapies have made great progress in the last decade owing to several pharmaceutical companies developing novel proprietary technologies for producing innovative peptide therapeutics. For instance, South Korea's Nanotechnology and Integrated Bioengineering Centre (NBICE), pharmaceutical company has developed its own novel peptide therapeutic discovery and delivery technology platform called TOPscovery. The company has also created a subsequent clinical pipeline using this novel technology platform which is based on target oriented peptide therapeutic discovery and has target tissue / cell penetrating peptide delivery platform to delivery protein or antibody or siRNA into the target tissue such as that of the cancer cells.

This peptide discovery platform TOPscovery is focused on resolving fibrosis in liver, lung and heart and additionally, the platform technology to target tissue penetrating peptide carrier (NPEP – TPP) can be applied to protein, antibody having intracellular targets, this increase the efficacy and decreases the side effects to non – target. The development of proprietary platforms and novel technologies has been an increasingly important factor that is boosting innovation the today's development of peptide based anti-cancer therapies.

Moreover, the increasing number of companies collaborating and investing in the field is also a signification factor driving the growth of peptide therapeutics. A major reason of this has been the development of novel technologies. With more pharmaceutical companies and biotechs advancing their portfolio with innovative products developed from novel platforms, more companies gain interest in field which could ultimately lead to more collaboration or investment, increasing the overall competitive landscape of the merging global market of anti – cancer peptide therapies.

The trend of collaboration not only extends the research and development capabilities for both the companies but it also allows for assessing the investigational peptide product candidates and likely have an impact on global peptide therapeutic market in terms of increasing the pipeline of cancer peptides, advancements in discovery and optimization of products and the possibility of investigational several different combinational strategies.

For instance, in first quarter of 2023, PeptiDream announced a collaborative arrangement with Ono Pharmaceuticals to discover and develop novel macrocyclic

constrained peptide-based drugs directed against targets chosen by Ono. Under the agreement, PeptiDream will apply its proprietary PDPS (Peptide Discovery Platform System) technology to identify and enhance macrocyclic constrained peptide drug candidates, while Ono will develop and commercialize the resulting peptide-based drugs globally under an exclusive license. PeptiDream will be eligible to receive an undisclosed upfront payment in addition to funding to carry out research, as well as added payments based on research, development and commercialization milestones based on global net sales.

In addition, the portfolio of novel cancer peptides with distinct characteristics expands as a result of the development of novel technologies and platforms by various pharmaceutical companies. This will provide diverse market opportunities for each and every therapeutic peptide product candidate. Furthermore, rise in the cancer prevalence and increasing research of the therapeutic use of cancer peptides is likely to be the key factors responsible for the growth of the market. Moreover, the increasing demand for effective and novel therapies can be further anticipated to bring more opportunities and growth in the market. Apart from this, awareness among healthcare professionals and patients about the significant adverse events associated with conventional cancer treatments will also lead to greater adoption towards peptide based therapeutics in cancer treatment.

Our report provides a comprehensive analysis about the current available anti-cancer peptide drugs and therapies while also providing information about their sales insight, patent information and their targeting cancer indication. Additionally, this report also includes the overall market perspective of peptides in different countries and provides a descriptive view on upcoming opportunities that might become available.

Contents

1. INTRODUCTION TO PEPTIDE THERAPEUTICS

- 1.1 Overview of Peptide Therapeutics
- 1.2 Classification Of Anticancer Peptides
- 1.3 Significance of Peptides as Cancer Therapeutics

2. GLOBAL CANCER PEPTIDE THERAPEUTICS MARKET INSIGHT

- 2.1 Current Market Scenario
- 2.2 Global Cancer Peptide Therapeutics Market Forecast

3. GLOBAL PEPTIDE CANCER THERAPEUTICS MARKET TREND BY REGION

- 3.1 Japan
- 3.2 South Korea
- 3.3 China
- 3.4 Australia
- 3.5 US
- 3.6 Europe

4. MARKETED CANCER PEPTIDES DRUGS INSIGHT – AVAILABILITY, COST, DOSAGE, INDICATION & PATENT INSIGHT

- 4.1 Firmagon (Degarelix)
- 4.2 Eligard (Leuprolide)
- 4.3 Lupron (Leuprolide Acetate)
- 4.4 Supprelin LA (Histrelin Acetate)
- 4.5 Gonax (Degarelix Acetate)
- 4.6 Trelstar (Triptorelin)
- 4.7 Decapeptyl SR (Triptorelin Acetate or Pamoate)
- 4.8 Velcade (Bortizomib)
- 4.9 Ninlaro (Ixazomib)
- 4.10 Kyprolis (Carfilzomib)
- 4.11 Istodax (Romidepsin)
- 4.12 Zoladex (Goserelin)
- 4.13 Cosmegen (Dactinomycin)
- 4.14 Somatuline Depot (Lanreotide)

- 4.15 Suprefact (Buserelin)
- 4.16 Sandostatin (Octreotide Acetate)
- 4.17 Bynfezia Pen (Octreotide)
- 4.18 Mepact (Mifamurtide)
- 4.19 Lutathera (Lutetium Lu 177 dotatate)
- 4.20 Netspot (Gallium Ga 68 dotatate)

5. MARKETED CANCER PEPTIDES DRUGS SALES INSIGHT (2019 -2023)

- 5.1 Lupron
- 5.2 Kyprolis
- 5.3 Zoladex
- 5.4 Lutathera
- 5.5 Sandostatin
- 5.6 Somatuline
- 5.7 Decapeptyl SR
- 5.8 Velcade
- 5.9 Ninlaro

6. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS OVERVIEW

- 6.1 By Company
- 6.2 By Country
- 6.3 By Indication
- 6.4 By Patient Segment
- 6.5 By Phase
- 6.6 By Drug Formulation

7. GLOBAL PEPTIDE CANCER THERAPEUTICS CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PEPTIDE SEGMENT

- 7.1 Research
- 7.2 Preclinical
- 7.3 Phase-I
- 7.4 Phase-I/II
- 7.5 Phase-II
- 7.6 Phase-II/III
- 7.7 Phase-III
- 7.8 Preregistration

7.9 Registered

8. MARKETED CANCER PEPTIDES CLINICAL INSIGHT BY COMPANY, COUNTRY & INDICATION

9. GLOBAL PEPTIDE CANCER THERAPY MARKET DYNAMICS

9.1 Favorable Market Parameters

9.2 Commercialization Challenges

10. TARGETS FOR THERAPEUTIC PEPTIDES

10.1 Signal Transduction Pathways

10.2 Cell Cycle Regulation

10.3 Cell Death Pathways

10.4 Tumor Suppressor Protein

10.5 Transcription Factors

11. PEPTIDE DRUGS V/S CONVENTIONAL CANCER THERAPEUTICS

11.1 Peptide v/s Chemotherapy

11.2 Peptide v/s Monoclonal Antibody

11.3 Peptide v/s Gene Therapy

11.4 Peptide v/s Immunotherapy

12. DIFFERENT APPROACHES OF PEPTIDES IN CANCER THERAPEUTICS

12.1 Hormonal Peptides

12.2 Peptide as Radionuclide Drug Carrier

12.3 Peptide Vaccines

12.4 Peptides as Cytotoxic Drug Carrier

12.5 Anticancer Peptides

12.6 Other Anticancer Drugs Closely Related to Peptides

13. APPLICATION OF PEPTIDES THERAPEUTICS & DETECTION METHODOLOGY BY CANCER

13.1 Colorectal Cancer

13.1.1 Peptides in Treatment of Colorectal Cancer

- 13.1.2 Proprietary Technologies
- 13.2 Lung Cancer
 - 13.2.1 Peptides in Treatment of Lung Cancer
 - 13.2.2 Proprietary Technologies
- 13.3 Pancreatic Cancer
 - 13.3.1 Peptide in Treatment of Pancreatic Cancer
 - 13.3.2 Proprietary Technologies
- 13.4 Gastric Cancer
 - 13.4.1 Peptides in Treatment of Gastric Cancer
 - 13.4.2 Proprietary Technologies
- 13.5 Breast Cancer
 - 13.5.1 Peptides in Treatment of Breast Cancer
 - 13.5.2 Proprietary Technologies
- 13.6 Prostate Cancer
 - 13.6.1 Peptides in Treatment of Prostate Cancer
 - 13.6.2 Proprietary Technologies

14. NEOANTIGEN VACCINE: AN EMERGING TUMOR IMMUNOTHERAPY

- 14.1 Personalized Neoantigen Based Vaccine in Cancer
- 14.2 Ongoing Clinical Advancements

15. VENOM PEPTIDES: NEW ERA FOR CANCER PEPTIDE THERAPY

- 15.1 Relevance of Venom Based Peptide Therapeutics
- 15.2 Recent Clinical Trials & Future Growth Avenues of Venom Peptides

16. COMPETITIVE LANDSCAPE

- 16.1 3B Pharmaceuticals
- 16.2 AsclepiX Therapeutics
- 16.3 Bicycle Therapeutics
- 16.4 Biohaven Labs
- 16.5 BrightPath Biotherapeutics
- 16.6 Bristol-Myers Squibb
- 16.7 Edinburgh Molecular Imaging
- 16.8 FogPharma
- 16.9 GE Healthcare
- 16.10 Gnubiotics Sciences

- 16.11 Harvard University
- 16.12 Heidelberg Pharma AG
- 16.13 IDP Pharma
- 16.14 Janux Therapeutics
- 16.15 Medikine
- 16.16 Modulation Therapeutics
- 16.17 Novartis
- 16.18 PeptiDream
- 16.19 Pharm-Sintez
- 16.20 Roche
- 16.21 Sanofi
- 16.22 Sapience Therapeutics
- 16.23 Second Genome
- 16.24 Viewpoint Molecular Targeting
- 16.25 Vigeo Therapeutics

List Of Figures

LIST OF FIGURES

Figure 1-1: Traditional Structure-Based Design Strategies Used in Peptide Drug Discovery

Figure 1-2: Classification of Anticancer Peptides

Figure 1-3: Significance of Peptides as Cancer Therapeutics

Figure 1-4: US - Per Unit Cost of Cancer Drugs (US\$)

Figure 1-5: Role of Peptides in Cancer Immunotherapy

Figure 2-1: Factors Driving The Global Market Of Cancer Peptides

Figure 2-2: Countries Leading In Research & Development Of Cancer Peptides

Figure 2-3: Global – Peptide Therapeutic Market Size (US\$ Billion), 2022 - 2029

Figure 2-4: Global – Peptide Oncology Drugs Market Size (US\$ Billion), 2022 - 2029

Figure 4-1: Firmagon – Patent Issue & Expiration Years

Figure 4-2: Firmagon – Price per Unit for Supply of 80 mg & 120 mg Powder for Subcutaneous Injection (US\$), June'2023

Figure 4-3: Firmagon - Starting & Maintenance Dosage (mg)

Figure 4-4: Firmagon – Treatment Costs of Initial Cycle and Maintenance Cycle (US\$), June'2023

Figure 4-5: Eligard - Cost of Different doses of Extended-Release Subcutaneous Powder for Injection (US\$), June'2023

Figure 4-6: Eligard – Recommended Dosage for Prostate Cancer on Monthly Basis (mg)

Figure 4-7: Eligard – Annual Treatment cost of Prostate Cancer using Different available Doses (US\$), June'2023

Figure 4-8: Lupron – Patent Issue & Expiration Year for Sustained Release Preparation

Figure 4-9: Lupron – Price for 7.5 mg, 22.5 mg, 30 mg & 40 mg Depot (US\$), June'2023

Figure 4-10: Lupron – Price for 3.75 mg & 11.25 mg Supply of Intramuscular Powder for Injection (US\$), June'2023

Figure 4-11: Lupron – Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 4-12: Lupron – Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US\$), June'2023

Figure 4-13: Histrelin – FDA Approval Years by Brand Name

Figure 4-14: Supprelin LA – Patent Approval & Expiration Years

Figure 4-15: Histrelin – Price for Single 50mg Supprelin LA Implant (US\$), June'2023

Figure 4-16: Gonax - Cost of 80mg & 120mg Supply of Powder for Subcutaneous Injection (US\$), June'2023

Figure 4-17: Gonax - Starting & Maintenance Dosage (mg)

Figure 4-18: Trelstar – Patent Issue & Expiration Year

Figure 4-19: Trelstar - Cost for a Supply of 3.75mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US\$), June'2023

Figure 4-20: Trelstar - Recommended Dose for Prostate Cancer Treatment (mg)

Figure 4-21: Trelstar – Annual Treatment Cost using 3.75 mg, 11.25mg & 22.5mg Powder for Intramuscular Injection (US\$), June'2023

Figure 4-22: Decapeptyl SR – Price for a Supply of 3mg, 11.25mg & 22.5mg Powder for Injection (GBP/US\$), June'2023

Figure 4-23: Decapeptyl SR - Recommended Dosage for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 4-24: Decapeptyl SR - Annual Treatment Cost of Prostate Cancer Treatment using Different Available Doses (US\$), June'2023

Figure 4-25: Velcade – Price for a Supply of 3.5 mg Powder for Injection (US\$), June'2023

Figure 4-26: Bortizomib – Price for a Supply of 1mg, 2.5mg & 3.5mg Powder for Injection (US\$), June'2023

Figure 4-27: Bortizomib – Price for a Supply of 3.5mg Powder for Intravenous Injection (US\$), June'2023

Figure 4-28: Bortizomib – Price for a Supply of 1.4 mL Powder for Intravenous Solution (US\$), June'2023

Figure 4-29: Ninlaro – Patent Issue & Expiration Years

Figure 4-30: Ninlaro – Price for 3 Capsule Supply & Price per Unit of Ninlaro Capsule (US\$), June'2023

Figure 4-31: Ninlaro – Recommended Dose & Dose Reductions for Treatment of Multiple Myeloma (Mg/Week)

Figure 4-32: Kyprolis – Issue & Expiration Years of Patents Assigned to Proteolix Inc

Figure 4-33: Kyprolis – Issue & Expiration Years of Patent Assigned to Cydex Pharmaceutical

Figure 4-34: Kyprolis – Issue & Expiration Years of Patents Assigned to Onyx Therapeutics

Figure 4-35: Kyprolis – Price of 10mg, 30mg & 60mg Intravenous Powder for Injection (US\$), June'2023

Figure 4-36: Kyprolis – Initial Dose & Maintenance Dose for Treatment of Multiple Myeloma (mg/m²/week)

Figure 4-37: Kyprolis - Initial Dose & Maintenance Dose as Monotherapy for Treatment of Multiple Myeloma (mg/m² Twice a Week)

Figure 4-38: Romidepsin – FDA Approval Year by Indication

Figure 4-39: Romidepsin – Price for a Supply of 10mg Branded & Generic Intravenous

Powder (US\$), June'2023

Figure 4-40: Romidepsin– Price for 5.5ml Supply & Price per ml of 5mg/ml Intravenous Solution (US\$), June'2023

Figure 4-41: Romidepsin – Monthly & Yearly Cost Of Treatment (US\$), June'2023

Figure 4-42: Zoladex - Cost of 3.6 mg & 10.8 mg Implant (US\$), June'2023

Figure 4-43: Zoladex – Recommended Dose for Prostate cancer Management on Monthly Basis (mg)

Figure 4-44: Zoladex – Annual Treatment Cost using 3.6mg & 10.8mg Implant (US\$), June'2023

Figure 4-45: Dactinomycin – Price for Generic & Branded 0.5 mg Powder for Injection (US\$), June'2023

Figure 4-46: Cosmegen – Annual Cost of Wilms Tumor Treatment (US\$), June'2023

Figure 4-47: Somatuline Depot – Price of 60mg/0.2 ml Supply & Price per ml of Somatulin Depot Subcutaneous Solution (US\$), June'2023

Figure 4-48: Somatuline Depot – Price of 90mg/0.3ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US\$), June'2023

Figure 4-49: Somatuline Depot – Price of 120mg/0.5ml Supply & Price per unit of Somatulin Depot Subcutaneous Solution (US\$), June'2023

Figure 4-50: Lanreotide – Price of 120mg/0.5ml Supply & Price per unit of Generic Lanreotide Subcutaneous Solution (US\$), June'2023

Figure 4-51: Somatuline Depot – Treatment cost of 1 Cycle & Annual Treatment Cost of GEP-NETs & Carcinoid Syndrome (US\$), June'2023

Figure 4-52: Suprefact – Price of 6.3mg & 9.45mg Depot (US\$), June'2023

Figure 4-53: Suprefact – Cost for a Supply of 1ml/ml Nasal Spray & Injectable solution (US\$), June'2023

Figure 4-54: Suprefact Injection – Recommended Initial Dose & Final Dose for Prostate Cancer Treatment (mg/Day)

Figure 4-55: Suprefact Depot – Recommended Dose for Prostate Cancer Treatment on Monthly Basis (mg)

Figure 4-56: Suprefact Depot – Annual Prostate Cancer Treatment Cost (US\$), June'2023

Figure 4-57: Sandostatin – Price for 10 Vial Supply & per Unit Price of 50mcg/ml Injectable Solution (US\$), June'2023

Figure 4-58: Sandostatin – Price for 10 Vial Supply & per Unit Price of 100mcg/ml Injectable Solution (US\$), June'2023

Figure 4-59: Sandostatin – Price for 10 Vial Supply & per Unit Price of 500mcg/ml Injectable Solution (US\$), June'2023

Figure 4-60: Sandostatin LAR – Price for Various Supplies of Intramuscular Powder for Injection (US\$), June'2023

- Figure 4-61: Octreotide – Price for 50 mcg/mL Vials of Generic Octreotide Injectable Solution (US\$), June'2023
- Figure 4-62: Octreotide – Price for 100 mcg/mL Vials of Generic Octreotide Injectable Solution (US\$), June'2023
- Figure 4-63: Octreotide – Price for 200 mcg/mL Vials of Generic Octreotide Injectable Solution (US\$), June'2023
- Figure 4-64: Octreotide – Price for 500 mcg/mL Vials of Generic Octreotide Injectable Solution (US\$), June'2023
- Figure 4-65: Octreotide – Price for 1000 mcg/mL Vials of Generic Octreotide Injectable Solution (US\$), June'2023
- Figure 4-66: Sandostatin - Mean Initial Dose for Treatment of Carcinoid Tumor & Vasoactive Intestinal Peptide Tumor (mg)
- Figure 4-67: Bynfezia Pen – Patent Issue & Expiration Year
- Figure 4-68: Bynfezia Pen – Price for 2.8ml Supply & Price per ml of 2500mcg/ml Subcutaneous Solution (US\$), June'2023
- Figure 4-69: Bynfezia Pen – Mean Dose for First 2 Week & Subsequent Weeks (mcg/day)
- Figure 4-70: Mepact - Recommended Number of Dose Administration/ Week for 12 & 24 Weeks Treatment
- Figure 4-71: Germany – Cost of Single Dose & Full Treatment (EUR/US\$), June'2023
- Figure 4-72: Lutathera – Patent Issue & Expiration Years
- Figure 4-73: Lutathera – RDP & ODE Regional Expiry Years
- Figure 5-1: Global - Lupron Annual Sales (US\$ Million), 2019-2021
- Figure 5-2: US - Lupron Annual Sales (US\$ Million), 2019-2021
- Figure 5-3: ROW - Lupron Annual Sales (US\$ Million), 2019-2021
- Figure 5-4: Kyprolis – Annual Sales Value (US\$ Million), 2018-2023
- Figure 5-5: Kyprolis – Annual Sales by Region (%), Q1'2023
- Figure 5-6: Global - Kyprolis Quarterly Sales Value (US\$ Million), 2022
- Figure 5-7: US - Kyprolis Quarterly Sales Value (US\$ Million), 2022
- Figure 5-8: ROW - Kyprolis Quarterly Sales Value (US\$ Million), 2022
- Figure 5-9: Global - Zoladex Annual Sales (US\$ Million), 2019-2023
- Figure 5-10: Regional - Zoladex Annual Sales (US\$ Million), 2023
- Figure 5-11: Regional - Zoladex Annual Sales (%), 2023
- Figure 5-12: Global - Zoladex Quarterly Sales (US\$ Million), 2022
- Figure 5-13: Regional - Zoladex Annual Sales (US\$ Million), 2022
- Figure 5-14: Regional - Zoladex Annual Sales (%), 2022
- Figure 5-15: US - Zoladex Annual Sales (US\$ Million), 2019-2023
- Figure 5-16: EU - Zoladex Annual Sales (US\$ Million), 2019-2023
- Figure 5-17: EM - Zoladex Annual Sales (US\$ Million), 2019-2023

- Figure 5-18: ROW - Zoladex Annual Sales (US\$ Million), 2019-2023
- Figure 5-19: Global - Lutathera Annual Sales (US\$ Million), 2019-2023
- Figure 5-20: Global - Lutathera Quarterly Sales (US\$ Million), 2022
- Figure 5-21: Global - Sandostatin Annual Sales (US\$ Million), 2019-2023
- Figure 5-22: Global - Sandostatin Quarterly Sales (US\$ Million), 2022
- Figure 5-23: Global – Somatuline Annual Sales (US\$ Million), 2019-2023
- Figure 5-24: Global – Somatuline Quarterly Sales (US\$ Million), 2022
- Figure 5-25: Global – Decapeptyl Annual Sales (US\$ Million), 2019-2023*
- Figure 5-26: Global – Decapeptyl Quarterly Sales (US\$ Million), 2022
- Figure 5-27: Global – Velcade Sales Value (US\$ Million), 2019-2023
- Figure 5-28: Regional – Velcade Sales Value (US\$ Million), 2022
- Figure 5-29: Regional – Velcade Sales Value (%), 2022
- Figure 5-30: Global – Velcade Quarterly Sales Value (US\$ Million), 2022
- Figure 5-31: Ninlaro – Annual Sales Value (US\$ Million), 2019-2023
- Figure 5-32: Ninlaro – Annual Sales Value (US\$ Million), 2022
- Figure 5-33: Ninlaro – Annual Sales by Region (%), Q1'2023
- Figure 5-34: Ninlaro – Annual Sales Value (US\$ Million), 2022
- Figure 5-35: Ninlaro – Annual Sales by Region (%), 2022
- Figure 6-1: Global - Peptide Cancer Drug Clinical Pipeline by Company (Number of Drugs), 2021 till 2026
- Figure 6-2: Global - Peptide Cancer Drug Clinical Pipeline by Country (Number of Drugs), 2023
- Figure 6-3: Global - Peptide Cancer Drug Clinical Pipeline by Indication (Number of Drugs), 2023
- Figure 6-4: Global - Peptide Cancer Drug Clinical Pipeline by Patient Segment (Number of 2023)
- Figure 6-5: Global - Peptide Cancer Drug Clinical Pipeline by Phase (Number of Drugs), 2023
- Figure 6-6: Global - Peptide Cancer Drug Clinical Pipeline by Drug Formulation (Number of Drugs), 2023
- Figure 9-1: Favorable Market Factors for Cancer Peptide Development
- Figure 9-2: Factors Challenging the Commercialization of Cancer Peptides
- Figure 10-1: Therapeutic Peptides Based on Their Biological Targets
- Figure 10-2: MAPK Signaling Pathways
- Figure 10-3: Cell Cycle in Eukaryotic
- Figure 10-4: Cell Death Pathways
- Figure 10-5: Features of Bcl-2 Family Proteins
- Figure 11-1: Limitations of Monoclonal Antibody
- Figure 11-2: Monoclonal Antibodies & Peptide Therapeutics – Cost of Production per

gram (US\$)

Figure 11-3: Pre-Requisite for Gene Therapy

Figure 11-4: Limitations of Gene Therapy

Figure 11-5: Drawbacks of Immunotherapy

Figure 12-1: Different Approaches of Peptide in Cancer Management

Figure 12-2: Mode of Action – LHRH Agonist & LHRH Antagonist

Figure 12-3: Effects of Somatostatin Analogs

Figure 12-4: Peptide Receptor Radionuclide Therapy

Figure 12-5: Mechanism of Peptide Vaccines

Figure 13-1: EO2040 – Study Initiation & Expected Completion Year, June'2023

Figure 13-2: EO4010 – Study Initiation & Competition Year, June'2023

Figure 13-3: ELI-002 – Study Initiation & Competition Year, June'2023

Figure 13-4: CBX-12 – Study Initiation & Completion Year'2023

Figure 13-5: Enterome – OncoMimics Platform

Figure 13-6: Elicio Therapeutics – The AMP Platform

Figure 13-7: Alphalex – Selective Targeting of Tumor Cells

Figure 13-8: Treos Bio – PolyPEPI Approach

Figure 13-9: UCPVax – Study Initiation & Expected Completion Year, June'2023

Figure 13-10: GRN-1201 – Study Initiation & Competition Year, June'2023

Figure 13-11: PeptiCRAd-1 – Study Initiation & Completion Year, June'2023

Figure 13-12: Owlstone Medical – EVOC Probes for Targeted Assessment of Biological Pathways

Figure 13-13: Bicycle Therapeutics – Simple Bicycles

Figure 13-14: Bicycle Therapeutics – Tandems

Figure 13-15: Bicycle Therapeutics – Higher Order Bicycles

Figure 13-16: Bicycle Therapeutics – Bicycle Toxin Conjugate

Figure 13-17: PeptiCRAd – Immunology

Figure 13-18: T-Win Vaccines – Mechanism of Action

Figure 13-19: MB1707 – Study Initiation & Completion Year, June'2023

Figure 13-20: BT5528 – Study Initiation & Completion Year

Figure 13-21: IMU-131 – Study Initiation & Completion Year

Figure 13-22: OTSGC-A24 – Study Initiation & Completion Year

Figure 13-23: Bicycle Therapeutics – Bicycle Toxin Conjugate

Figure 13-24: HER-Vaxx – Active Immunization Mechanism of Action

Figure 13-25: Stress-Induced Post-Translational Modifications Cell Surface Peptides

Figure 13-26: Moditope – Mechanism of Action

Figure 14-1: Benefits of Neoantigens

Figure 14-2: Steps of Producing Neoantigen Vaccine

Figure 14-3: Neoantigen Vaccine - Mode of Action

Figure 15-1: Advantages of Venom Peptides

List Of Tables

LIST OF TABLES

Table 1-1: Source or Chemical Nature of Early Peptides

Table 4-1: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma

Table 12-1: Peptides in Clinical Trials

Table 13-1: Peptides & Their Targets in Colorectal Cancer

Table 13-2: Colorectal Cancer – Peptide Based Therapies Currently Under Clinical Trials

Table 13-3: Lung Cancer - Peptide Based Therapies Currently Under Clinical Trials

Table 13-4: Antigens Utilized as Molecular Targets

Table 13-5: Pancreatic Cancer - Peptide Based Therapies Currently Under Clinical Trials

Table 13-6: Gastric Cancer – - Peptide Based Therapies Currently Under Clinical Trials

Table 13-7: Breast Cancer - Peptide Vaccines under Development

Table 13-8: Prostate Cancer – Examples of Therapeutic Peptides

Table 14-1: Global – Late Stage Neoantigen Vaccines

Table 15-1: Other Venom Peptides in Cancer Therapy

I would like to order

Product name: Global Peptide Cancer Drug Market, Dosage, Price, Sales & Clinical Trials Insight 2029

Product link: <https://marketpublishers.com/r/GF9ED2C8979AEN.html>

Price: US\$ 3,600.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF9ED2C8979AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970